Tisotumab vedotin is an intravenously administered antibody-drug conjugate targeting tissue factor proposed to treat recurrent or metastatic cervical cancer that has progressed on or following chemotherapy.

If you have a Hayes login, click here to view the full report on the Knowledge Center.